Startup profile · funding coverage
CMR Surgical funding, valuation and investors
Develops the Versius modular surgical-robotics platform.
Keep track of CMR Surgical
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Strategic preferred equity (announced; subject to closing)
Approximately $400M (£300M) · October 12, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
Not publicly disclosed
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Cambridge, United Kingdom
Investors in latest funding
Lead: Stryker
Overview
Medical-robotics company developing the Versius surgical robotic system for minimally invasive procedures.
Why CMR Surgical is interesting
CMR is one of the few independent soft-tissue surgical robotics companies with FDA-cleared technology and meaningful international procedure volume, making it a strategic challenger to incumbent robotic-surgery platforms.
Product & use cases
Versius is a modular robotic-assisted surgery system designed for minimally invasive procedures and compact operating-room deployment.
Funding history (newest first)
Strategic preferred equity (announced; subject to closing)
2026-10-12 Approximately $400M (£300M)- Stryker (lead)
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover CMR Surgical's financing or category context.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.